Education
About Us
Working with TipRanks
Follow Us
CureVac (CVAC)
NASDAQ:CVAC
CVAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $5.28
Previous CloseN/A
Volume1.54M
Average Volume (3M)656.07K
Market Cap
$736.26M
Enterprise Value$306.49M
Total Cash (Recent Filing)-€60.63M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)4.0
Beta1.15
Next Earnings
May 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding225,155,870
10 Day Avg. Volume754,924
30 Day Avg. Volume656,068
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.17Price Target Upside60.06% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCVAC received FDA clearance to initiate the Phase 1 dose-finding trial of CVHNLC in squamous non-small cell lung cancer.
Financial PositionThe €400M payment from the amended GSK licensing agreement supports the company's financial position.
Patent RulingsA positive infringement ruling in Germany would trigger damage assessment proceedings, potentially benefiting Curevac.
Bears Say
Market CompetitionRoyalty-bearing flu/COVID programs with GSK are unlikely to drive much value due to their late entries into the market.
Pipeline DevelopmentPipeline assets from CureVac are still in the very early stages of development and await clinical proof-of-concept before significant value can be assigned.
Restructuring ChallengesThe analyst reiterates an underperform rating due to significant derisking needed for pipeline assets amid restructuring and hesitance on the impact of GSK-partnered assets.
---
Ownership Overview
― Insiders
0.07% Mutual Funds
0.01% Other Institutional Investors
98.73% Public Companies and
Individual Investors
CVAC FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was $2.21 and its highest was $5.28 in the past 12 months.
What is CureVac’s market cap?
CureVac’s market cap is $736.26M.
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is May 21, 2025 which is in 23 days.
How were CureVac’s earnings last quarter?
CureVac released its earnings results on Apr 10, 2025. The company reported -$0.171 earnings per share for the quarter, beating the consensus estimate of -$0.176 by $0.006.
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CureVac have?
CureVac has 225,155,870 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
CureVac reported an EPS of -$0.171 in its last earnings report, beating expectations of -$0.176. Following the earnings report the stock price went down -4.027%.
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is Platinum Investment Management. It holds CureVac’s shares valued at 0.
---
CureVac Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.17 (60.06% Upside)
$5.17 (60.06% Upside)
Blogger Sentiment
Neutral
CVAC Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $579.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.37%
12-Months-Change
Fundamentals
Return on Equity
28.12%
Trailing 12-Months
Asset Growth
-4.53%
Trailing 12-Months
Company Description
CureVac
CureVac N.V. is a biotechnology company that specializes in the development of messenger RNA (mRNA) technology for medical purposes. Based in Germany, the company is involved in the fields of prophylactic and therapeutic vaccination, cancer immunotherapy, and molecular therapy. CureVac's core products and services revolve around its innovative mRNA technology platform, which is designed to use the body's own machinery to produce proteins that can fight diseases.
---
CVAC Company Deck
---
CVAC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
CureVac has demonstrated strong financial health with a solid cash runway and strategic partnerships, particularly with GSK. Significant progress in oncology and patent validation are positive indicators. However, operational challenges, including a major restructuring and associated costs, pose concerns.Read More>---
CVAC Stock 12 Month Forecast
Average Price Target
$5.17
▲(60.06% Upside)
Technical Analysis
Xencor
―
Vir Biotechnology
―
Nurix Therapeutics
―
Praxis Precision Medicines
―
AbCellera Biologics
―
---